A Trial of SHR-A1904 in Patients With Advanced Pancreatic Cancer
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The study is being conducted to assess the safety and tolerability of SHR-A1904 in patients
with with advanced pancreatic cancer and to determine the dose-limiting toxicity (DLT),
maximum tolerated dose (MTD), and recommended phase II dose (RP2D) of SHR-A1904